News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
aTyr Pharma Receives FDA Fast Track Designation For Resolaris To Treat Facioscapulohumeral Muscular Dystrophy (FSHD) 10/24/2016
Advaxis (ADXS) Announces GOG-0265 12-Month Overall Survival Rate Of 37.5% In Stage 2 10/24/2016
Cidara (CDTX) Announces Data From Studies Of Novel Antifungal CD101 To Be Presented At ACCP And IDweek Annual Meetings 10/24/2016
Alkermes (ALKS)' Success Puts the Spotlight on Cerecor, Eli Lilly (LLY)'s 2015 Deal 10/21/2016
A Look at BioMarin (BMRN)'s Potential Blockbuster and the Science Behind It All 10/21/2016
Roche (RHHBY)'s Avastin Successor Flunks Key Study, Turns Hope to Tecentriq Instead 10/21/2016
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916 10/21/2016
Dermira (DERM) Presents Data From DRM01 Phase IIb Clinical Program At Annual Meeting For Dermatologists 10/21/2016
What You May Have Missed: Critics Point to Problems With Celgene (CELG)’s Crohn’s Drug Trial Design 10/20/2016
First Patient Cohort Data From BioTime (BTX)'s OpRegen Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016 10/20/2016
Alexion (ALXN) Release: FDA Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD) 10/20/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Meets Primary And Secondary End Points In Metabolic Syndrome And Type 2 Diabetes Phase 2 Clinical Trial 10/20/2016
HedgePath Pharmaceuticals Announces Further Positive Interim Data In Its Phase II(B) Cancer Trial 10/20/2016
Sanifit Announces Initiation Of First Clinical Trial Of SNF472 In Patients With Calciphylaxis 10/20/2016
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016
Omeros (OMER) Announces Positive Data From OMS721 Phase II Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy 10/20/2016
Tobira (TBRA) Announces Late-Breaking Oral Presentation Of CENTAUR Phase IIb Trial Results At The American Academy For The Study Of Liver Diseases Annual Meeting 10/20/2016
Gilead (GILD)'s GS-4997 Meets Goals in Mid-Stage NASH Trial, But Flunks Studies In PAH And DKD 10/20/2016
Madrigal Announces The Initiation Of A Phase 2 Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
Omeros (OMER) Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist In Cocaine Abuse 10/19/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016
Comeback Kid Exelixis (EXEL) Could Pose a Huge Threat to Biotech Giants Bristol-Myers Squibb (BMY) and Pfizer (PFE) 10/18/2016
FDA Slaps Hold on Regeneron (REGN), Teva (TEVA)'s Pain Drug Fasinumab 10/18/2016
Soligenix (SNGX) Announces Publication Of Its Phase 2 Clinical Trial Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 10/18/2016
Insmed (INSM) Announces Publication Of Phase II Study Of ARIKAYCE In Treatment-Refractory Nontuberculous Mycobacterial Lung Disease 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
The Medicines Company (MDCO) Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si 10/18/2016
InDex Pharmaceuticals AB: Results From InDex Pharmaceuticals' COLLECT Study Well Received At UEGW 10/18/2016
A Look at CRISPR, 'Biotech's Biggest Discovery of the Century,' and the 3 Companies Knee Deep in It 10/17/2016
Celgene (CELG) Shows Off Crohn's Disease Data in Small Mid-Stage Study 10/17/2016
Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial 10/17/2016
SciFluor Life Sciences, LLC Announces First Patients Dosed In Retinal Program With Investigational New Drug Application For SF0166 Topical Ophthalmic Solution 10/17/2016
PanOptica, Inc. Reports Positive Results From Phase 1/2 Clinical Trial Of PAN-90806, A Novel Topical Anti-VEGF Eye Drop 10/17/2016
Regeneron (REGN) And Teva (TEVA) Provide Update On Fasinumab Clinical Development Programs 10/17/2016
Envisia Therapeutics Releases ENV515 (Travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma 10/17/2016
ContraVir Release: CMX157 Advances Head-To-Head Phase 2a Clinical Study In Hepatitis B Patients With Favorable Recommendation From DSMB 10/17/2016
Zynerba (ZYNE) Provides Clinical Update For Lead Development Candidates – ZYN001 And ZYN002 10/17/2016
Celgene (CELG) Release: Oral Ozanimod Efficacy And Safety Results From Phase II TOUCHSTONE Extension Trial In Patients With Ulcerative Colitis To Be Presented At UEGW And American College of Gastroenterology 10/17/2016
Eiger Biopharma Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From EMA 10/17/2016
Addex Therapeutics (ADXN.SW) To Conduct Phase IIa Proof Of Concept Study Of Dipraglurant In Focal Cervical Dystonia 10/17/2016
MorphoSys AG Presents Updated Clinical Results For MOR202 At Medical Conference 10/17/2016
Omeros (OMER) Announces Positive Data From OMS721 Phase 2 Clinical Trial In Renal Diseases 10/17/2016
3 Biotechs With Cancer Drugs That Could Win Approval in 2017 10/14/2016
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin 10/14/2016
After Setback, Adaptimmune (ADAP) Revamps T Cell Study 10/14/2016
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion For Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin 10/14/2016
Adverum Biotechnologies Provides Update On Alpha-1 Antitrypsin Deficiency Program 10/14/2016
Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 10/14/2016
ESMO 2016 Takeaways: Don't Miss Celldex (CLDX), Exelixis (EXEL) and Tesaro (TSRO) 10/13/2016
The Medicines Company (MDCO) To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY 2016 Annual Meeting And The ISAP 25th Annual Meeting 10/13/2016
Flex Pharma (FLKS) Provides FLX-787 Nocturnal Leg Cramp Regulatory And Clinical Update 10/13/2016
Allegro Ophthalmics LLC Announces Positive Topline Results From DEL MAR Phase 2b Trial Evaluating Luminate In Patients With Diabetic Macular Edema 10/13/2016
BIOCAD Biotechnology Company Announces The Start Of Phase 2 Clinical Trials Of An Innovative Drug To Treat Severe Psoriasis 10/13/2016
ContraVir Release: CMX157 Demonstrates 99% Viral Load Reduction In Ongoing Head-To-Head Phase 2a Clinical Study Vs. Viread In Hepatitis B Patients 10/13/2016
Can-Fite BioPharma (CFBI) Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH 10/13/2016
SELLAS Life Sciences Group Announces Positive Interim Phase II Results From Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients 10/13/2016
Dermira (DERM) To Present Data From DRM01 And DRM04 Clinical Programs At Fall Clinical Dermatology Conference 10/13/2016
Heat Biologics Remains On Track To Achieve Multiple Topline Data Readouts This Quarter 10/13/2016
NeuroVive (NVP) Stock Craters After Discontinuing Acute Kidney Injury Program 10/13/2016
Trevi Therapeutics Announces Positive Results From Phase II Trial In Prurigo Nodularis 10/13/2016
Synairgen (SNG.L) Stock Tanks After Partner AstraZeneca PLC (AZN) Halts Asthma Drug Trial 10/12/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Significantly Reduces Liver Fibrosis In Patients With Alström Syndrome 10/12/2016
Viamet Release:FDA Grants QIDP and Fast Track Designations to VT-1161 for Treatment of Recurrent Vulvovaginal Candidiasis 10/12/2016
Bay Area Exelixis (EXEL)' Cabometyx Beats the Pants Off Pfizer (PFE)'s Sutent in Mid-Stage Kidney Cancer Study 10/11/2016
Agilis Biotherapeutics Announces Authorization Of Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency 10/11/2016
Investors Relieved as Supernus (SUPN) ADHD Drug Meets Goals in Phase IIb Study 10/11/2016
The Ripple Effect of Alnylam (ALNY)'s Blow-up Yesterday 10/10/2016
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib 10/10/2016
Xenetic Biosciences Reports Positive Topline Data From Third Cohort Of Phase 2 Dose-Escalation Trial Of Erepoxen For Anemia 10/10/2016
Ariad (ARIA) Presents Updated Long-Term Follow-Up Results From The Phase 1/2 Trial On Investigational Drug Brigatinib At 2016 ESMO Meeting 10/10/2016
AstraZeneca PLC (AZN) Release: Durvalumab Shows Promising Preliminary Early Data In Lung And Head & Neck Cancers 10/10/2016
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At The European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study 10/10/2016
Aprea Announces First Patients Enrolled In Phase II Clinical Study Of APR-246 For The Treatment Of High-Grade Serous Ovarian Cancer 10/10/2016
Boehringer Ingelheim Release: Overall Survival Data From LUX-Lung 7 Head-To-Head Trial Of Gilotrif (Afatinib) Versus Iressa (Gefitinib) Presented At ESMO 10/10/2016
CytRx (CYTR) Presents Interim Results From On-Going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress 10/10/2016
PharmaMar Announces Positive Results From Its Phase II Study With Lurbinectedin In BRCA 1/2 - Associated Metastatic Breast Cancer At The ESMO 2016 Congress 10/10/2016
Celldex (CLDX) Release: Phase II Study Of Single-Agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint And Demonstrates Clinically Meaningful Duration Of Response 10/10/2016
Dynavax (DVAX) Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, At ESMO Annual Congress 10/10/2016
Viralytics Ltd (VLA.AX) Release: CAVATAK YERVOY Combination Demonstrates Promising Clinical Response Rates In Advanced Melanoma 10/10/2016
Karolinska Development AB Portfolio Company Aprea Enrolls First Patients In Phase II Trial Of APR-246 In Ovarian Cancer 10/10/2016
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 2 Combination Trial Of PROSTVAC And Ipilimumab In Patients With Localized Prostate Cancer 10/10/2016
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH 10/7/2016
Why SCYNEXIS, Inc. (SCYX) Is Making A Run 10/7/2016
Boston Therapeutics Reports Positive Topline Data From Proof Of Concept Asia Trial 10/7/2016
SCYNEXIS, Inc. (SCYX) Announces Complete Results From Two Phase II Studies Of Oral SCY-078 In Patients With Candida Spp. Infections And Closing Of A $15 Million Term Loan 10/6/2016
ARCA biopharma Announces Randomization Of First European Patients In GENETIC-AF Phase IIB/III Clinical Trial 10/6/2016
Catabasis (CATB) Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress 10/6/2016
aTyr Pharma Presents Additional Data For Resolaris Phase 1b/2 Trial In Adult Patients With Facioscapulohumeral Muscular Dystrophy At The 21st International Annual Congress Of The World Muscle Society 10/6/2016
The Medicines Company (MDCO) Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si 10/6/2016
First Patients Dosed In TopiVert’s Phase IIa Proof-Of-Concept Study In Moderate To Severe Ulcerative Colitis 10/6/2016
A Closer Look at the Pipelines Pfizer (PFE) Inherited From Recent Acquisitions 10/5/2016
Capricor Therapeutics, Inc. Completes Enrollment In Phase II ALLSTAR Clinical Trial 10/5/2016
Vtesse Announces Dosing Of First Patient In Germany For Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 10/5/2016
Karyopharm (KPTI) To Present Updated SIGN Phase II Clinical Data At European Society Of Medical Oncology 2016 Annual Meeting 10/5/2016
Bone Therapeutics Reports Positive Efficacy Data For The ALLOB Phase IIA Spinal Fusion Trial 10/5/2016
RedHill Biopharma (RDHL) Announces Initiation Of Phase II Study With YELIVA In Hepatocellular Carcinoma At Medical University of South Carolina 10/5/2016
Gilead (GILD) Might Avoid Fighting Celgene (CELG), But Allergan (AGN), Intercept Pharma (ICPT) and Novartis AG (NVS) Await 10/4/2016
Viking Therapeutics (VKTX) Doses First Patient In Phase 2 Clinical Trial Of VK2809 In Patients With Hypercholesterolemia And Non-Alcoholic Fatty Liver Disease 10/4/2016
Otonomy (OTIC) Successfully Completes Phase II Clinical Trial Of OTIPRIO In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes 10/4/2016
Theranexus Has Obtained An Orphan Drug Designation From The FDA For THN102 In The Treatment Of Narcolepsy 10/4/2016
Catabasis (CATB) Completes Target Enrollment For Part B Of The MoveDMD Trial, A Phase II Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy 10/4/2016
Amgen (AMGN) Release: Study Results Published In Journal Of Clinical Oncology Show BLINCYTO (Blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 10/4/2016
Milo Biotechnology Announces FDA Orphan Drug Designation For Treatment Of Inclusion Body Myositis 10/4/2016
RespireRx (RSRX) Retracts Efficacy Data In September 12, 2016 Press Release Announcing Preliminary Top-Line Analysis Of Safety And Efficacy Data From Duke University Phase 2A Clinicial Trial Of CX 1739 10/4/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection 10/4/2016
Trial Failure Forces Bay Area's Threshold Pharma (THLD) to Cut Almost a Quarter of Workforce 10/3/2016
Allegro Ophthalmics LLC Announces Last Patient Enrolled In PACIFIC Phase IIb Clinical Trial Of Luminate For Non-Proliferative Diabetic Retinopathy 10/3/2016
TheraVida, Inc. Release: THVD-102 Demonstrates Promising Potential As An Orally Administered Treatment For Hyperhidrosis 10/3/2016
Castle Creek Pharma Announces Late-Breaking Results At EADV Of Phase 2 Topical Diacerein 1% Data In Patients With Epidermolysis Bullosa Simplex (EBS) 10/3/2016
Pfizer (PFE) on Track to Have 3 Blockbuster Cancer Drugs 10/3/2016
Regeneron (REGN) Faces Setback as Eylea Combo Drug Flunks Phase II Test 9/30/2016
Arbutus Biopharma (ABUS) Reports Interim Multi-Dose Results From Phase II Clinical Trial Of ARB-1467 In Patients With Chronic HBV Infection 9/30/2016
Quantum Genomics Corp. Reports Positive Top-Line Results From Phase IIa Trial Of QGC001 In Hypertension 9/30/2016
FDA Tags AbbVie (ABBV)'s HCV Regimen With Breakthrough Tag 9/30/2016
Aurinia (ISA.TO) Announces That Voclosporin Achieves Primary And All Pre-Specified Secondary Endpoints In Its Phase IIb AURA-LV Study For Lupus Nephritis (LN) 9/30/2016
Genocea (GNCA)'s Genital Herpes Candidate Successful in Mid-Stage Trial 9/29/2016
Marinus Pharma (MRNS) Release: Ganaxolone Reduces Seizures In Females With PCDH19 Pediatric Epilepsy 9/29/2016
Galectin (GALT) Stock Craters After Phase IIa NASH Failure 9/28/2016
Kite Pharma (KITE) Claims Success for Phase II CAR-T Study, Stock Soars 9/28/2016
Matinas BioPharma Commences Patient Dosing In NIH-Sponsored Phase IIa Study With Lead Anti-Infective Candidate MAT2203 9/28/2016
Neurim Pharmaceuticals Announces First Patients' Enrollments In ReCOGNITION - Phase II Clinical Trial Of Piromelatine For Mild Alzheimer's Disease 9/28/2016
Two New Trials Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer To Be Presented During Presidential Session At ESMO 2016 9/28/2016
Galera Announces Presentation Of One-Year Follow-up Data From A Phase 1b/2a Study Of GC4419 In The Reduction Of Severe Oral Mucositis 9/28/2016
BeyondSpring Pharmaceuticals Announces First Patient Enrolled In Phase 1b/2 Investigator-Initiated Trial Of Plinabulin Plus Nivolumab For Non-Small Cell Lung Cancer 9/27/2016
Ansun BioPharma Announces Two Publications Showing Inhibitory Effects Of DAS181 On Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (hMPV) 9/27/2016
Actinium (ATNM.OB) Announces Initiation Of Phase II Clinical Trial Of Actimab-A In Patients Newly Diagnosed With Acute Myeloid Leukemia Over Age 60 9/27/2016
Ipsen (IPN.PA) Announces Data Presentations Of Cabozantinib (Cabometyx), Lanreotide (Somatuline® Autogel®) And Telotristat Ethyl* At The European Society For Medical Oncology (ESMO) 2016 Congress 9/27/2016
SAGE Therapeutics (SAGE) Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting 9/27/2016
Clinical Data Support Mechanism Of Action And Patient Selection Biomarker For Imprime PGG, Biothera's Phase II Cancer Immunotherapy 9/27/2016
Shkreli Called it: Mast Therapeutics (MSTX) Begins Winding Down Vepoloxamer Programs 9/26/2016
AbbVie (ABBV) Announces Submission Of A Supplemental New Drug Application For Ibrutinib (IMBRUVICA) For Treatment Of Marginal Zone Lymphoma 9/26/2016
Achillion (ACHN) Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen’s Phase II Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naïve HCV 9/26/2016
Lipocine (LPCN) Announces Positive Top-Line Phase IIb Study Results For LPCN 1111, A Next Generation Oral Testosterone Replacement Therapy 9/26/2016
Axovant (AXON) Receives FDA Fast-Track Designation For Intepirdine As An Investigational Treatment For Dementia With Lewy Bodies 9/26/2016
ERYtech Pharma Completes Patient Enrollment In Phase 2 Trial Of Eryaspase (GRASPA) For Pancreatic Cancer 9/26/2016
SciClone (SCLN) Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market 9/26/2016
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease 9/26/2016
Summit Therapeutics Receives FDA Fast Track Status for DMD Treatment 9/26/2016
Abeona Therapeutics Enrolls First Patient In Phase 2 For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 9/26/2016
Cytori (CYTX) Partner Kerastem Completes Enrollment Of U.S. Phase II Trial For Early Stage Hair Loss 9/26/2016
Alnylam (ALNY) Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 9/26/2016
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016
Investors Beware: Thin CAR-T Data Could Make or Break Juno (JUNO) and Kite Pharma (KITE) 9/23/2016
Gilead (GILD) Terminates Phase II/III Study of Ulcerative Colitis Drug 9/23/2016
Kerastem Completes Enrollment in US Phase II Hair Growth Clinical Trial 9/23/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 9/23/2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Chronic Graft-Versus Host Disease 9/23/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea 9/23/2016
Nordic Nanovector: Safety Review Committee Supports Dose Escalation With Betalutin In Lymrit 37-01 Trial Pending Safety Data From Cohort Receiving Higher Pre-Dosing 9/23/2016
Fundación MAPFRE Presents The Results Of Personalized Cell Therapy For Treating Spinal Cord Injury 9/23/2016
Neuraltus Pharmaceuticals, Inc. Initiates Confirmatory Phase 2 Study Of NP001 In Patients With Amyotrophic Lateral Sclerosis 9/22/2016
ASIT Biotech Announces The Initiation Of A Phase IIa Clinical Study Of Its Second Product Candidate Hdm-ASIT+TM For House Dust Mite Rhinitis 9/22/2016
Syros Pharma Announces First Patient Enrolled In Phase II Clinical Trial Of SY-1425 In Genomically Defined Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome 9/22/2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 9/22/2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Chronic Graft-Versus Host Disease 9/22/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea 9/22/2016
Bionomics Limited (BNO.AX) Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder 9/21/2016
DBV Tech Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow’s Milk Protein Allergy 9/21/2016
Actinium (ATNM.OB) To Host Webinar To Provide Update On Actimab-A Phase II Clinical Trial 9/21/2016
SanBio, Inc. Begins Clinical Trial Of Regenerative Cell Medicine For Patients With Traumatic Brain Injury In Japan 9/21/2016
BiondVax Pharmaceuticals Phase 2b European Trial: Last Patient Out 9/21/2016
Cerecor Inc. Announces Completion Of Enrollment In Phase II Clinical Trial With CERC-301 As An Oral, Adjunctive Treatment Of Major Depressive Disorder 9/21/2016
Cidara (CDTX) Selects First Development Candidate From Its Cloudbreak Immunotherapy Discovery Platform 9/21/2016
bluebird bio (BLUE) Release: Lentiglobin Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into EMA’s PRIME Program 9/21/2016
Synthetic Biologics (SYN) Announces Completion Of Enrollment For Phase 2b Proof-Of-Concept Clinical Trial For SYN-004 (Ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms 9/20/2016
Windtree Therapeutics (WINT) Announces FDA Fast Track Designation For AEROSURF 9/20/2016
BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 9/20/2016
Tyme Announces William K. Oh, M.D., Chief Of The Division Of Hematology And Medical Oncology At Mount Sinai, As Special Advisor For A Phase II Trial For Recurrent Prostate Cancer Patients Being Planned At Mount Sinai Hospital 9/20/2016
Sunovion Announces Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 9/20/2016
Enteris Biopharma's "Feasibility To Licensing" Partner, Cara Therapeutics (CARA), Advances Peptelligence-Engineered CR845 Into Phase 2b Clinical Trial In Chronic Pain 9/19/2016
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting 9/19/2016
Catalyst Pharma (CPRX) Announces Publication Of CPP-115 Clinical Efficacy Data For Infantile Spasms In Epilepsy & Behavior Case Reports 9/19/2016
Stealth Biotherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics In The Elderly 9/19/2016
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016
Quark Pharmaceuticals Inc. Chief Scientist Provides An Overview Of The Company's Clinical And Nonclinical Pipelines 9/19/2016
Astellas (ALPMY), Vical  (VICL)'s Experimental Herpes Vaccine Flunks Mid-Stage Test 9/19/2016
NovaBay (NBY)’ Auriclosene Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation 9/19/2016
Teva (TEVA) Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease 9/19/2016
Akebia (AKBA) Announces Publication Of Phase IIb Data For Vadadustat In Non-Dialysis Patients With Anemia Related To Chronic Kidney Disease 9/19/2016
Novartis AG (NVS) Says Experimental Drug Helps Chronic Migraine Sufferers 9/19/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Interim Results From Trek Therapeutics' Phase 2 Study Show Triple Combination Therapy Achieves 100% SVR4 In Genotype 4 HCV Patients 9/16/2016
Amgen (AMGN) Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine 9/16/2016
Celgene (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 Radiance Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Celgene International Sárl (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
BioTime (BTX) Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries 9/16/2016
Retrotope Announces Phase I/II Clinical Trial Results Of RT001 In Treatment Of Friedreich’s Ataxia 9/16/2016
Cumberland Pharmaceuticals (CPIX) Announces New Program To Develop Portaban For Portal Hypertension 9/15/2016
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 9/15/2016
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 9/15/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Inhibikase Therapeutics Receives FDA Clearance To Initiate Clinical Trials For Potential Disease-Modifying Therapies To Treat Parkinson's Disease 9/14/2016
Asterias Biotherapeutics AST-OPC1 Treatment For Spinal Cord Injury Patients Shown To Help Patients Paralyzed From The Neck Down Regain Function In The Arms And Hands 9/14/2016
Euroscreen S.A. Completes Enrollment In Phase II Trial Of Lead Candidate ESN364 In Menopausal Hot Flashes 9/14/2016
Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results With SRX246 In Intermittent Explosive Disorder 9/14/2016
Despite Trial Deaths, Juno (JUNO) Could Still Be the CAR-T Leader 9/13/2016